

REF A11A01923

REAGENT 1 28 mL

REAGENT 2 6 mL



IVD 

HORIBA ABX SAS
Parc Euromédecine
Rue du Caducée
BP 7290
34184 Montpellier Cedex 4
FRANCE

ABX Pentra Ig A CP

- Pentra C400

Diagnostic reagent for quantitative *in vitro* determination of Immunoglobulin A (IgA) in serum or plasma by immunoturbidimetry.

Application Release

Serum, plasma: IgA_CP (not for use in the USA)

1.xx

Intended Use (not for use in the USA)

ABX Pentra Ig A CP reagent is intended for the quantitative *in vitro* diagnostic determination of Immunoglobulin A (IgA) in serum and plasma by turbidimetry.

Measurement of this immunoglobulin aids in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents.

Clinical Interest (1, 2, 3)

The human immunoglobulin classes (IgG, IgA, IgM, IgE and IgD) are a group of functionally and structurally closely related glycoproteins. Human IgA has a molecular weight of about 160 000 daltons and consists of two identical heavy chains and two identical light chains which are bound together by disulfide bonds in a characteristic Y-shaped form. Serum IgA is produced by plasma cells (B-cells) and represents about 15% of all soluble immunoglobulin classes. About 90% of the serum IgA is monomeric the rest is dimeric and polymeric. Most of IgA is not present in serum but on the surface of mucous membranes. In the mucosal tissues of the lung and the gastrointestinal tract IgA is released by plasma cells in a dimeric form. The two Y-shaped pieces are bound together not only by a joining chain but also by a special peptide called secretory component. This IgA type is called secretory-IgA. It is normally not present in human serum but in other body fluids like sweat, tears, gastrointestinal and bronchial secretions. The main

function of serum-IgA is to bind to antigens and trigger further catabolism of the antigen.

Decreased serum-IgA concentrations occur in primary as well as in secondary immunodeficiency syndromes. A high increase of one immunoglobulin class due to multiple myeloma may result in a decrease in other immunoglobulin classes like IgA. Increased loss of IgA due to severe enteritis may result in a decreased concentration. Increased IgA concentrations can be observed in severe infections and autoimmune diseases. Especially inflammatory processes of the liver may result in increased serum IgA levels. Like for other Ig-classes many forms of myeloma produce high amounts of monoclonal or polyclonal IgA. Quantitative serum-IgA determination is necessary for differential diagnostics of these diseases.

All methods for IgA quantitation are calibrated for polyclonal serum-IgA. The quantitation of monoclonal IgA is not standardized and values may differ for different reagents and methods. Values should only be used for follow up studies. Monoclonal immunoglobulinemia requires detailed differential diagnostic investigation in addition to the quantitative determination.

Method

Immunoturbidimetric test.

Endpoint determination of the concentration of IgA done by photometric measurement. It is an antigen-antibody-reaction of the antibodies of IgA with the IgA that is present in the sample.

Reagents

ABX Pentra Ig A CP is ready-to-use.

ABX Pentra Ig A CP

Reagent 1 (R1):

TRIS pH 7.5	100 mmol/L
NaCl	150 mmol/L

Reagent 2 (R2):

TRIS pH 8.0	100 mmol/L
NaCl	300 mmol/L

Anti-human IgA antibody (goat) < 1%

ABX Pentra Ig A CP should be used according to this notice. The manufacturer cannot guarantee its performance if used otherwise.

Handling

1. Remove both caps of the cassette.
2. If present, remove foam by using a plastic pipette.
3. Position the protective cap (GBM0969) on the cassette.
4. Place the cassette into the refrigerated reagent compartment.

Calibrator

For calibration, use:

ABX Pentra SP Cal (A11A01927) (not included)
5 x 1 mL (5 levels)

This calibrator is traceable against CRM 470-CAP/IFCC. Calibration is carried out by using:

- NaCl solution 9 g/L for Cal 0 (concentration 0 mg/L).
- **ABX Pentra SP Cal**, which contains five calibrator levels at different concentrations. Each vial is labelled from 1 to 5. The relation level/calibrator concentration is mentioned in the annex.

Control ^a

For internal quality control, use:

- **ABX Pentra N MultiControl** (1300054414) (not included)
10 x 5 mL (lyophilisate)
- **ABX Pentra P MultiControl** (1300054415) (not included)
10 x 5 mL (lyophilisate)

Each control should be assayed daily and/or after a calibration.

The frequency of controls and the confidence intervals should correspond to laboratory guidelines and country-specific directives. You should follow federal, state and local guidelines for testing quality control materials. The results must be within the range of the defined confidence limits. Each laboratory should establish a procedure to follow if the results exceed these confidence limits.

Materials Required but not Provided ^a

- Automated clinical chemistry analyzer: Pentra C400
- Calibrator: **ABX Pentra SP Cal** (A11A01927)
- Controls:
 - **ABX Pentra N MultiControl** (1300054414)
 - **ABX Pentra P MultiControl** (1300054415)
- NaCl solution: 9 g/L
- Standard laboratory equipment.

Specimen ^b

This device intended testing population is general population.

- Serum.
- Plasma in lithium heparin or EDTA.

Anticoagulants other than those listed have not been tested by HORIBA Medical and are therefore not recommended for use with this assay.

Stability (4)

- At 20 - 25°C: 8 months
- At 4 - 8°C: 8 months
- At -20°C: 8 months

Reference Range ^c

Each laboratory should establish its own reference ranges. The values given here are used as guidelines only.

Adults (5): 0.70 - 4.00 g/L

Clinical sensitivity and specificity, positive predictive value and negative predictive value are not commonly reported for this analyte. This is largely attributed to the fact that this analyte is not sole indicator for the intended purpose

^aModification: control removed.

^bModification: modification of specimen stability.

^cModification: information added.

ABX Pentra Ig A CP

and patient treatment decision making. To arrive at a diagnosis and a course of treatment, results from others routine clinical chemistry tests should be used in conjunction with other diagnostic information and the attending health-care professional's evaluation of the patient's condition.

Storage and Stability

Stability before opening:

Stable up to the expiry date on the label if stored at 2-8°C.

Stability after opening:

Refer to the paragraph "Performance on Pentra C400".

Do not freeze.

Waste Management

- Please refer to local legal requirements.
- This reagent contains less than 0.1% of sodium azide as a preservative. Sodium azide may react with lead and copper to form explosive metal azides.

General Precautions ^d

- This reagent is for professional *in vitro* diagnostic use only.
For laboratory use.
- For prescription use only.
- This reagent is classified as non-hazardous in compliance with regulation (EC) N°.1272/2008.
- **Reagent 2 (R2):**
Warning: This reagent is obtained from substances of animal origin. Consequently, it should be treated as potentially infectious and handled with the appropriate cautions in accordance with good laboratory practices (6).
- Do not pipette by mouth.
- Do not replenish the reagents.
- Do not swallow. Avoid contact with skin and mucous membranes.
- Observe the standard laboratory precautions for use.
- The reagent cassettes are disposable and should be disposed of in accordance with the local legal requirements.

- Please refer to the SDS associated with the reagent.
- Do not use the product if there is visible evidence of biological, chemical or physical deterioration.
- Do not use the product if the recommended storage conditions, including temperature, are not followed.
- User must be trained by a HORIBA Medical representative before attempting to operate the device.
- It is the user's responsibility to verify that this document is applicable to the reagent used.
- For technical assistance, you can call +33 (0)4 67 14 15 16.
- Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the country in which the user and/or the patient is established.

Performance on Pentra C400

Lot to Lot Variability ^e

The recovery of samples (serum and plasma) done during QC release of three consecutive lots of reagent shows that the lot to lot variability is within specification: < 10%.

Serum, plasma

The performance data listed below are representative of performance on HORIBA Medical Systems.

Number of tests: 100 tests

On Board Reagent Stability

Once opened, the reagent cassette placed in the refrigerated Pentra C400 compartment is stable for 28 days.

Sample volume: 2 µL/test

Detection Limit ^f

The detection limit is determined according to CLSI (NCCLS), EP17-A2 protocol (7) and equals 0.07 g/L.

Limit of Quantitation ^g

The limit of quantitation is determined according to CLSI (NCCLS), EP17-A protocol (8) and equals 0.106 g/L.

^dModification: general precautions modification.

^eModification: chapter added.

^fModification: data added.

^gModification: modification of quantitation limit.

ABX Pentra Ig A CP

Accuracy and Precision

Repeatability (within-run precision)

Repeatability according to the recommendations found in the Valtec protocol (9) with samples tested 20 times:

- 2 controls
- 3 specimens (low / medium / high levels)

	Mean value g/L	CV %
Control specimen 1	1.02	0.95
Control specimen 2	3.24	0.63
Specimen 1	0.93	0.53
Specimen 2	1.83	0.71
Specimen 3	3.73	0.93

Reproducibility (total precision)

Reproducibility according to the recommendations found in the CLSI (NCCLS), EP5-A2 protocol (10) with samples tested in duplicate for 20 days (2 series per day):

- 2 controls
- 3 specimens (low / medium / high levels)

	Mean value g/L	CV %
Control specimen 1	1.03	4.3
Control specimen 2	3.36	2.9
Specimen 1	1.08	2.9
Specimen 2	2.09	1.6
Specimen 3	4.11	1.6

Measuring Range^h

The assay confirmed a measuring range from 0.106 g/L to the highest calibration point.

The measuring range is extended up to x 3 with the automatic post-dilution.

The reagent linearity has been assessed up to 8.00 g/L according to the recommendations found in the CLSI (NCCLS), EP6-A protocol (11).

Correlationⁱ

Patient samples: Serum

Number of patient samples: 150

Specimens are correlated with a commercial reagent taken as reference according to the recommendations found in the CLSI (NCCLS), EP09c protocol (12).

Values ranged from 0.32 g/L to 5.94 g/L.

The equation for the allometric line obtained using Passing-Bablok regression procedure (13) is:

$$Y = 0.9664 X - 0.06815 \text{ (g/L)}$$

with a correlation coefficient $r^2 = 0.996$.

Interferences^j

Haemoglobin:	No significant influence is observed up to 290 $\mu\text{mol/L}$ (500 mg/dL).
Triglycerides:	No significant influence is observed up to a triglyceride concentration of 12.9 mmol/L (1124.4 mg/dL).
Total Bilirubin:	No significant influence is observed up to 400 $\mu\text{mol/L}$ (23.4 mg/dL).
Direct Bilirubin:	No significant influence is observed up to 400 $\mu\text{mol/L}$ (23.4 mg/dL).
Ibuprofen:	No significant influence is observed up to 2.43 mmol/L (50.10 mg/dL).
Acetaminophen:	No significant influence is observed up to 1.32 mmol/L (20 mg/dL).
Acetylsalicylic Acid:	No significant influence is observed up to 3.62 mmol/L (65.16 mg/dL).

Other limitations are given by Young as a list of drugs and preanalytical variables known to affect this methodology (14, 15).

Prozone Effect

No antigen excess has been detected up to a concentration of 50 g/L.

Calibration Stability

The reagent is calibrated on Day 0. The calibration stability is checked by testing 2 control specimens.

The calibration stability is 14 days.

Note: A recalibration is recommended when reagent lots change, and when quality control results fall outside the range established.

Reference

1. Thomas L., editor. Clinical laboratory diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft (1998): 667-78.
2. Johnson AM, Rohlfes EM, Silverman LM. Proteins. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders Company (1999): 507-12.

^hModification: modification of measuring range.

ⁱModification: modification of correlation.

^jModification: modification of interferences.

ABX Pentra Ig A CP

3. Bartl R, Hoechtlen-Vollmar W, Thomas L. Monoclonal immunoglobulins. In: Thomas L., editor. Clinical laboratory diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft (1998): 742-58.
4. Use of anticoagulants in diagnostic laboratory investigations. WHO Publication WHO/DIL/LAB/99.1 Rev 2 (2002): 35.
5. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Biennvenu J et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur. J. Clin. Chem. Clin. Biochem. (1996) **34**: 517-20.
6. Council Directive (2000/54/EC). Official Journal of the European Communities. No. L262 from October 17, 2000: 21-45.
7. Evaluation of detection capability for clinical laboratory measurement procedures. Approved Guideline, 2nd ed., CLSI (NCCLS) document EP17-A2 (2012) **32** (8).
8. Protocols for determination of limits of detection and limits of quantitation. Approved Guideline, CLSI (NCCLS) document EP17-A (2004) **24** (34).
9. Vassault A, Grafmeyer D, Naudin C et al. Protocole de validation de techniques (document B). Ann. Biol. Clin. (1986) **44**: 686-745.
10. Evaluation of Precision Performance of Quantitative Measurement Method. Approved Guideline, CLSI (NCCLS) document EP5-A2 (2004) **24** (25).
11. Evaluation of the Linearity of Quantitative Analytical Methods. Approved Guideline, CLSI (NCCLS) document EP6-A (2003) **23** (16).
12. Measurement Procedure Comparison and Bias Estimation Using Patient Samples. Approved Guideline, 3rd ed., CLSI (NCCLS) document EP09c (2018) **38** (12).
13. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J. Clin. Chem. Clin. Biochem. (1983) **21**: 709-720.
14. Young DS. Effects of Drugs on Clinical Laboratory Tests. 4th Edition, Washington, DC, AACC Press (1997) **3**: 143-163.
15. Young DS. Effects of Preanalytical Variables on Clinical Laboratory Tests. 2nd Edition, Washington, DC, AACC Press (1997) **3**: 120-132.

